Krystal Biotech says it's on schedule for filing for license with FDA
May 09, 2022 at 16:48 PM EDT
"Our primary objective in 2022 is to prepare for the potential approval and launch of B-VEC in the U.S.," the company's CEO said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|